Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Reference17 articles.
1. Abdel-Meguid, T.A., H.A. Mosli, H. Farsi, A. Alsayyad, A. Tayib, M. Sait, and A. Abdelsalam. 2018. Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: a prospective controlled study. The Canadian Journal of Urology 25 (2): 9273–9280.
2. Polackwich, A.S., and D.A. Shoskes. 2016. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer and Prostatic Diseases 19 (2): 132–138.
3. Paulis, G. 2018. Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy. Res Rep Urol 10: 75–87.
4. Shimizu, S., Y. Nagao, T. Kataoka, S. Kamada, T. Shimizu, Y. Higashi, and M. Saito. 2020. Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats. European Journal of Pharmacology 882: 173313.
5. Hiramatsu, I., A. Tsujimura, M. Soejima, A. Yoshiyama, Y. Nagashima, K. Ishikawa, Y. Uesaka, T. Nozaki, T. Ogishima, M. Shirai, I. Mitsuhashi, S. Sugimura, T. Mizuno, K. Noto, Y. Shigeta, J. Takasu, S. Honda, S. Iwata, and S. Horie. 2020. Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. International Journal of Urology 27 (1): 53–57.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献